55 results about "Hepatocyte function" patented technology

Surfaces useful for cell culture comprise a support to which is bound a CAR material, and, bound to the CAR material, an ECM protein, or a biologically active fragment or variant thereof such as elastin, fibronectin, vitronectin, laminin, collagen I, collagen III, collagen IV, and collagen VI. Also, optionally present on the surface is an active factor, preferably a polycationic polymer or a biologically active fragment or variant thereof, such as polyethyleneimine (PEI), poly-D-lysine (PDL), poly-L-lysine (PLL), poly-D-ornithine (PDO) or poly-L-ornithine (PLO). This surface is used in cell culture to promote cell attachment, survival, and / or proliferation of primary liver cells. The invention also relates to methods utilizing this surface, such as methods for attachment, survival, and / or proliferation of cells. Further disclosed is the use of the surface in cell culture with serum-free medium. Methods of screening using the surface of the invention are also disclosed.

The inevention discloses a novel silk protein-galactosylation chitosan macroporous carrier with the specificity of hepatic cells, a preparation method thereof, and a method for culturing the hepatic cells under the condition of microgravity rotary culture using same. Compared with the normal solid frame material, the novel microcarrier has larger surface area / volume and has a sinusoid structure which is extremely similar to a hepatic sinus structure in human body, thereby being better convenient for the hepatic cells to be stuck on the frame material, the mutual contact among cells, the transmission of oxygen gas and nutrient component, and the discharge of metabolites, and further heightening the culture density of the hepatic cells and the function of the hepatic cells.

The invention discloses a medicine compound for curing hepatitis, which includes following ingredients and proportion: glycyrrhetic acid monoamine 1-200 shares, L-hydrochloric acid cysteine 1-200 shares, and one of sodium chloride, anhydrous sodium sulfite and ethylenediamine sodium acetic acid or the compound of then, the sodium chloride is 1-1000 shares, the anhydrous sodium sulfite is 1-200 shares, the ethylenediamine sodium acetic acid is 1-100 shares; it also discloses the medicine compound and the manufacturing method and the use, the medicine is compound solution, it can be applied to liver poisoning resisting, reduces the transaminase, recovers the functions of cell; it is mainly applied to cure the chronic hepatitis.

The invention describes the use of an injectable form of Idebenone to protect against hepatic damage, improve recovery from liver trauma, poisoning, vapor intoxication, degenerative diseases, hepatocyte function loss and pathology associated with inflammation or infection. The use of injectable Idebenone restores liver function, suppresses elevated enzyme levels, decreases alcoholic and drug abuse associated syndromes, symptoms of acute hepatitis of various origins, the consequences of liver reperfusion and other signs of liver damage.

The invention relates to a (KYL) organ preservation solution. The organ preservation solution is prepared from the following raw materials by weight (dosage g / L): 40 to 45 grams of sucrose, 1 to 3 grams of reducibility glutathione, 3 to 4 grams of adenosine triphosphate, 0.12 to 0.18 gram of ulinastatin, 0.6 to 0.8 gram of magnesium sulfate, 0.5 to 0.8 gram of sodium hydroxide, 2 to 3 grams of potassium dihydrogen phosphate, 2 to 4 grams of disodium hydrogen phosphate, 0.6 to 1 gram of radix salviae miltiorrhizae, 0.6 to 0.9 gram of notoginseng, and 10 to 12 grams of glycine. The organ preservation solution has the advantages that: the organ preservation solution has simple preparation and an equivalent preservation effect compared with the UW solution; the organ preservation solution has a better effect than the UW solution regarding the protection for the hepatocyte functions, the hepar microcirculation and the sinus hepaticus endothelial cells; and the organ preservation solution has low price.

The present invention relates to a viral liver disease treating pharmaceutical composition, and discloses a traditional Chinese medicine composition, which is prepared from cape jasmine, tuckahoe, salvia miltiorrhiza, cortex lycii, radix pseudostellariae and amomum villosum lour through a suitable preparation method. According to the present invention, the traditional Chinese medicine compositionhas advantages of low raw material cost, easily-available raw materials and simple preparation method, and can significantly reduce the viral amount of viral hepatitis and improve the function of liver cells.

The invention discloses a culturing method for improving the in-vitro differentiation phenotype and function of hepatic cells. The culturing method is characterized by comprising the following steps that the hepatic cells are adopted as seed cells, a porous silk protein scaffold is taken as an in-vitro culturing carrier of the hepatic cells, the hepatic cells, hepatogenic interstitial cells and an extracellular matrix are inoculated to the porous silk protein scaffold according to a certain proportion, and the porous silk protein scaffold is put in a simulated hepatic cell in-vitro culturing environment to be cultured. A three-dimensional hepatic cell co-culturing system built through the method not only can be applied to tissue-engineered hepatic cell function units, but also can be applied to in-vitro evaluation of an influence of drugs on a hepatic metabolism enzyme and hepatic toxicity detection, and therefore a novel screening and evaluating tool is supplied to new drug research and development.

The invention discloses liver-protecting nutritional composition which comprises, by weight, 18-22 parts of pawpaw superfine powder, 8-12 parts of giant knot weed superfine powder, 8-12 parts of jujube superfine powder, 7-12 parts of hawthorn superfine power, 5-15 parts of tuchahoe powder, and 3-8 parts of Tengcha superfine powder. Formulation of the liver-protecting nutritional composition is reasonable. As being made of superfine powders, the liver-protecting nutritional composition has greatly reserved biological activity. Human bioavailability is improved. Since the liver-protecting nutritional composition is utilized for preparing the liver-protecting national food, hepatocyte function of patients with liver disease can be conditioned effectively, catabolism of fat granule is improved, liver microenvironment is improved remarkably, necrotic tissue regeneration is improved, catabolism load of the liver is released, and rehabilitation is improved after the patients with liver diseases eat the liver-protecting national food.

The invention discloses compound astragalus polysaccharide injection used for pigs and a preparation method thereof. Every 100L of compound astragalus polysaccharide injection used for the pigs contains the following raw materials, such as 0.5-5kg of astragalus polysaccharide, 1-10kg of lincomycin, 5-30kg of analginum, 1-10kg of inosine, 3-6L of 2-hydroxyl ethylamine and the like, wherein the astragalus polysaccharide can accelerate the lymphocyte to be converted and increased in value and accelerate the phagocytic function of macrophage; the lincomycin has strong antibiosis efficacy; the astragalus polysaccharide and the lincomycin are organically combined to perform an antiviral function, widen an antibacterial spectrum and enhance a targeted action on bacteria; the analginum has various functions of resisting bacterium, diminishing inflammation, carrying out antipyretic action, relieving pain and the like; and the inosine is favorable for restoring the function of a damaged hepaticcell. Above medicines have a reasonable formula, can simultaneously carry out symptomatic treatment and etiological treatment by aiming at diseases, has quick curative effect on mixed infection of pig virus and bacteria and treats both principal and secondary aspect of the disease, the medicine resistance of the pathogenic microorganism is lowered, the clinic symptom of a diseased pig is alleviated, and therefore the pig is quickly restored.

Provided are compositions for long-term maintenance of functional hepatocytes in culture, a method for improved maintenance of functional hepatocytes in vitro, and functional hepatocytes cultures according to the methods. The culture compositions include at least: one activator of adenylate cyclase, one TGFbeta inhibitor, one Notch inhibitor, one Wnt inhibitor, and / or one BMP inhibitor. The combinations of compounds are added to any hepatocyte cell culture medium in an effective amount to maintain functional hepatocyte function in vitro, long term. The hepatocytes can be used for in vitro drug research and to model liver disease.

The invention relates to a composition for protecting the liver, detoxifying, preventing and treating liver and related metabolic diseases. The main ingredients are 200-250 parts of kudzu root, 200-220 parts of poria cocos, 50-60 parts of dandelion, and licorice 40-50 parts, 160-180 parts of chicory, 5-6 parts of soybean oligosaccharides, 10-15 parts of soybean peptide powder, 5-8 parts of glycine, 2-3 parts of lycopene; the auxiliary material is 5-6 parts of edible corn starch 6 parts, 4‑6 parts of sodium carboxymethylcellulose. The invention also provides a preparation method of the composition. The prescription of the present invention adopts natural traditional Chinese medicine materials of the same origin as food and medicine, supplemented with nutrients, scientific compatibility, promotes drug excretion, protects the liver, improves liver cell function, and performs non-drug intervention on fatty liver and related metabolic system problems , the same source of food and medicine avoids secondary damage to the liver caused by drug treatment, and achieves the effect of "clearing the liver and protecting the liver without hurting the liver".

The present disclosure provides a culture medium formulation comprising human serum that can enhance functions of primary human hepatocytes, improve morphology, promote bile canaliculi formation and extend hepatocyte functional lifetime in vitro for over 10 weeks as compared to ˜3-4 weeks when using a conventional culture medium containing serum from bovine sources. The provided long-term culture model can be used to screen drugs for their efficacious and / or toxic effects over several weeks, improve drug-transporter assays via the larger bile canaliculi network, and to model several chronic liver diseases such as hepatitis, type 2 diabetes, malaria, liver fibrosis, liver cancer, and fatty liver disease.

The present invention provides compounds and compositions containing reduced nicotinamide riboside for use in methods of prevention and / or treatment of liver disease and / or conditions. In one embodiment of the invention, the compounds and compositions of the invention improve liver by: maintaining or improving a liver function; maintaining or improving a hepatocyte function; and improving liver recovery and regeneration after injury, transplantation or surgery. In another embodiment of the invention, compounds and compositions of the invention may be used in methods to prevent and / or treat liver diseases and / or conditions such as: non-alcoholic fatty liver disease (NAFLD), alcoholic fatty liver disease, hepatic steatosis, cirrhosis and / or recovery and regeneration after liver injury, transplantation or surgery.

The invention discloses a technical method for co-cultivating hepatocytes and hepatic sinusoidal endothelial cells and application of the technical method. The technical method is characterized in that a hepatic sinusoidal endothelial cell line is subjected to anaerobic cultivation for a certain period of time, and then the hepatic sinusoidal endothelial cell line is harvested and co-cultured witha hepatocyte line at a certain ratio. Co-culture with the hepatic sinusoidal endothelial cell line can partially simulate a liver environment in a human body, hepatocyte functions are facilitated, after the hepatic sinusoidal endothelial cells are activated by hypoxia, the ability of promoting the hepatocyte functions is enhanced, and no exogenous endothelial cell activator is needed, the introduction of exogenous materials is reduced, and subsequent cell application is facilitated. The invention further provides the application of the co-culture method in fields including drug screening, bioartificial liver preparation and the like.

The invention discloses a plush-type bioreactor artificial liver system. The plush-type bioreactor artificial liver system comprises a plasma separating / recirculating part and a bioreactor circulating part which are mutually connected through a pipe, wherein the plasma separating / recirculating part comprises a blood transfusion port, a blood pump, an arterial ampulla, a plasma separator, a venous ampulla and a blood retransfusion port which are sequentially connected; a blood inlet, a plasma outlet and a blood cell outlet are formed in the plasma separator; the blood inlet is communicated with the outlet of the arterial ampulla; an artificial liver bioreactor comprises a reactor housing, and a plurality of pieces of plush and a plurality of hollow fiber tubes, which are arranged inside the inner chamber of the reactor housing; the plurality of pieces of plush and the plurality of hollow fiber tubes are arranged in parallel and are alternately spaced. The plush-type bioreactor artificial liver system has the beneficial effects as follows: the plush-type bioreactor artificial liver system significantly increases the adherent area of liver cells in the reactor, improves the uniformity of liver cell distribution, can maintain good cell activity, and benefits maximum achievement of functions of the liver cells, so that the best therapeutic effect is achieved.

The invention relates to the technical field of medicines, in particular to a culture method for long-term maintenance of functional state of human primary hepatocytes. The method is of culturing thehuman primary hepatocytes in a hepatocyte amplification medium with the inoculum density of 3 x 104 / cm2. According to the method in the invention, the function of the primary hepatocyte (PHH) can bemaintained within at least 30 days through high-density culture in the hepatocyte amplification culture medium, the long-term in vitro culture and function maintenance of the primary human hepatocytecan be realized, and a basic guarantee is provided for drug metabolism evaluation and hepatocyte treatment.

With the present invention, liver cell function research of a human fetal liver cell line L-02 is performed, and the human fetal liver cell line L-02 is adopted in liver cell transplantation. The research results show that: the L-02 cells have good liver cell functions, can express a plurality of liver cell specificity factors, wherein the liver cell specificity factors comprise albumin, bilirubin glucuronosyltransferase, blood coagulation factors, transaminase and the like. 90% hepatectomy-induced acute liver failure (ALF) rat model experiment results show that: the survival time of the ALF rats can be effectively prolonged with the L-02 cells, the tumorigenesis risk does not exist, the L-02 cells is expected to be the good cell source for liver cell transplantation, bioartificial liver, medical researches related to the liver cell functions, and the like, and is applicable for treatment of the ALF, liver cell function researches, and other medical fields.

The present invention belongs to the field of medicine technology, and is especially a kind of medicine composition and its preparation process. The medicine composition is prepared with kurarinone 4-400 weight portions, glutathione 3-300 weight portions, and tiopronin 1-100 weight portions. The medicine composition may be prepared into different pharmaceutically acceptable forms, preferably injection and oral preparation. It has the pharmacological activities of antagonizing virus, improving liver cell function, antagonizing liver fibrosis, regulating immunity, diminishing inflammation, etc. and may be used in treating various hepatic diseases, viral hepatosis, medicinal hepatosis, alcoholic hepatosis, etc.

The invention discloses a method for preparing immortalized hepatocytes with reversible liver functions and application of the immortalized hepatocytes, and relates to the field of biomedicine. A Tet-on system is applied to the hepatocytes, and the functions of the hepatocytes are enhanced through the Tet-on system. The Tet-on system has the characteristics of high efficiency, accuracy, safety and reversibility. Therefore, a novel immortalized hepatocyte is prepared, reversible regulation and control of hepatocyte functions can be realized by adding or removing tetracycline analogues, and reversible enhancement of the hepatocyte functions is promoted. The preparation method is simple and easy to implement, the culture cost is low, seed cells are derived from immortalized hepatocytes, and clinical transformation is easy.

The invention is directed to methods for culturing cells so that the cells are induced to differentiate into cells that express a hepatic stellate phenotype. The invention is also directed to cells produced by the methods of the invention. The cells are useful, among other applications, for treatment of liver deficiencies, liver metabolism studies, and liver toxicity studies, fibrogenic studies, or to support hepatocyte function in co-culture setting.

The invention discloses application of artificial livers in gene toxicology and animal toxicology, which enables liver tissues to form conditions of structure, PH values, nutrition, temperature, concentration of CO2 and the like which are analogous to those inside human body on cell chips, thereby the liver tissues can live for long on cell chips, expressions of functional genes of liver cells such as Albumin and HNF4 reach a level similar to that inside human body, large-scaled cultivation of liver cell chips is achieved, reaction of artificial livers in toxicology and pharmacology is quantified, and comparison of reaction among artificial livers, animal experiments and excised livers, and external experiments of liver cells to medicine is made, and existing experiments on live animals can be replaced.

The invention provides application of ellagic acid to preparation a medicine for preventing and / or treating a nonalcoholic fatty liver disease and liver injury. The invention proves that the ellagic acid is an Nrf2 agonist, and by up-regulating expression of Nrf2 and downstream antioxidant factors and transporters thereof, the ellagic acid increases the level of glutathione (GSH) in the liver, andmeanwhile, reduces the level of reactive oxygen species (ROS) in hepatocytes, oxidative stress reaction and inflammatory reaction are reduced, the functions of hepatocytes are maintained, and therefore the effect of treating the nonalcoholic fatty liver disease (NAFLD) is achieved. In addition, the ellagic acid can increase the level of the GSH in the liver by up-regulating the expression of Nrf2and the downstream antioxidant factors and transporters thereof, so that the hepatotoxicity of a normal dose of N-acetyl-p-aminophenol (APAP) increased by the NAFLD is prevented. The ellagic acid hasgood application prospects in the preparation of NAFLD treatment drugs and APAP hepatotoxicity prevention drugs.

The invention discloses a hepatocyte culture solution which comprises dexamethasone with the final concentration of 1-20 [mu] M, curcumin with the final concentration of 1-20 [mu] M and a basic culture medium, the hepatocyte culture solution has the advantages of being simple in component and low in cost, hepatocytes with enhanced functions are obtained through quantitative induction, and application of the hepatocytes to treatment of liver diseases is accelerated. According to the culture method for enhancing the functionality of the hepatocytes and the used hepatocyte culture solution, sufficient nutrition can be provided for growth of the target hepatocytes, and expression of related metabolic enzymes and albumin genes of the target cells can be induced.

The invention discloses a hepatocyte in-vitro co-culture system as well as a construction method and application thereof. The hepatocyte in-vitro co-culture system comprises an extracellular matrix, hepatocytes and 3T3-J2 fibroblasts, wherein the hepatocytes are planted on the extracellular matrix, and the 3T3-J2 fibroblasts are laid on the surfaces of the hepatocytes. The construction method of the hepatocyte in-vitro co-culture system comprises the following steps: inoculating 3T3-J2 fibroblasts on a temperature-sensitive culture dish, carrying out culturing and stripping to obtain the hepatocyte in-vitro co-culture system. The hepatocyte in-vitro co-culture system provided by the invention provides a three-dimensional form closer to an in-vivo liver tissue microenvironment for human hepatocytes, ensures tight hepatocyte / hepatocyte interconnection and hepatocyte / supporting cell interaction, and can effectively enhance and maintain hepatocyte functions; and the system can be used forlong-term drug evaluation.

The invention relates to a manufacture method for biology artificial liver biology reactor that includes the following steps: expanding stem cell expanding to 1*10^7 OM, adding into cultivating liquid for suspensoid after assimilating and centrifuging, adding into hollow fiber filterer, and laying into incubator to take continuing expansion and changing inducing type cultivating liquid, the stem cell could have the cell having liver cell function. The invention has stable stem cell resource, and could save cost. It has little immunity source polarity, long time keeping activity, and is benefit for cure.

The invention discloses a traditional Chinese medicine composition for clearing away heat and toxic materials and removing stasis, and a preparation method thereof. The composition includes involucrate stahlianthus rhizome, rose rhodobryum herb, tangerine seeds, Chinese honey bee larva, bark of elm tree and persimmon leaf. The composition can enhance organism adaptation and digestive organ functions, improve insufficiency of the spleen and promote tissue metabolism; the composition has the efficacy of clearing away heat and toxic materials and removing stasis; in animal experiments, high and low dose groups have a certain inhibition effect on liver tumor, the physiological status of mice is good, and the survival rates of 45 days are respectively 100% and 80%; the composition has no toxicand side effects on human bodies, and can strengthen nutrition, inhibit liver tumor, repair hepatocyte functions, reverse liver cirrhosis and reduce the mortality of severe hepatitis; and the composition has synchronous therapeutic effects on complications of the liver tumor.

The invention is directed to methods for culturing cells so that the cells are induced to differentiate into cells that express a hepatic stellate phenotype. The invention is also directed to cells produced by the methods of the invention. The cells are useful, among other applications, for treatment of liver deficiencies, liver metabolism studies, and liver toxicity studies, fibrogenic studies, or to support hepatocyte function in co-culture setting.